Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/342957
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampMónica, Fabíola Zakia-
dc.contributor.authorunicampDe Nucci, Gilberto-
dc.typeArtigopt_BR
dc.titleTadalafil for the treatment of benign prostatic hyperplasiapt_BR
dc.contributor.authorMonica, Fabiola Zakia-
dc.contributor.authorDe Nucci, Gilberto-
dc.subjectHiperplasia prostáticapt_BR
dc.subject.otherlanguageProstatic hyperplasiapt_BR
dc.description.abstractIn men, lower urinary tract symptoms (LUTS) are primarily attributed to benign prostatic hyperplasia (BPH). Therapeutic options are targeted to relax prostate smooth muscle and/or reduce prostate enlargement. Areas covered: This article reviews the major preclinical and clinical data on PDE5 inhibitors with a specific focus on tadalafil. It includes details of the role of the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) - PDE5 pathway in the LUT organs (bladder and prostate) in addition to the available data on tadalafil in patients with LUTS secondary to BPH with or without erectile dysfunction (ED). Expert opinion: Preclinical and clinical data have clearly demonstrated that PDE5 inhibitors induce bladder and prostate relaxation, which contributes to the improvement seen in storage symptoms in both animal models of bladder and prostate hypercontractility. Tadalafil is effective both as a monotherapy and add-on therapy in patients with LUTS secondary to BPH. Furthermore, as LUTS-BPH and ED are urological disorders that commonly coexist in aging men, tadalafil is more advantageous than alpha 1-adrenoceptors and should be used as the first option. Tadalafil is a safe and tolerable therapy and unlike alpha 1- adrenoceptors and 5-alpha reductase inhibitors, which can cause sexual dysfunctions, tadalafil improves sexual functionpt_BR
dc.relation.ispartofExpert opinion on pharmacotherapypt_BR
dc.publisher.cityAbingdonpt_BR
dc.publisher.countryReino Unidopt_BR
dc.publisherTaylor & Francispt_BR
dc.date.issued2019-
dc.language.isoengpt_BR
dc.description.volume20pt_BR
dc.description.issuenumber8pt_BR
dc.description.firstpage929pt_BR
dc.description.lastpage937pt_BR
dc.rightsFechadopt_BR
dc.sourceWOSpt_BR
dc.identifier.issn1465-6566pt_BR
dc.identifier.eissn1744-7666pt_BR
dc.identifier.doi10.1080/14656566.2019.1589452pt_BR
dc.identifier.urlhttps://www.tandfonline.com/doi/abs/10.1080/14656566.2019.1589452pt_BR
dc.date.available2020-06-08T21:48:22Z-
dc.date.accessioned2020-06-08T21:48:22Z-
dc.description.provenanceSubmitted by Sanches Olivia (olivias@unicamp.br) on 2020-06-08T21:48:22Z No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2020-06-08T21:48:22Z (GMT). No. of bitstreams: 0 Previous issue date: 2019en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/342957-
dc.contributor.departmentDepartamento de Farmacologiapt_BR
dc.contributor.departmentDepartamento de Farmacologiapt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.subject.keywordTadalafilpt_BR
dc.subject.keywordLower urinary tractpt_BR
dc.subject.keywordProstatept_BR
dc.subject.keywordBladderpt_BR
dc.subject.keywordPhosphodiesterase type 5pt_BR
dc.subject.keywordErectile dysfunctionpt_BR
dc.subject.keywordCyclic GMPpt_BR
dc.identifier.source000463526300001pt_BR
dc.creator.orcid0000-0002-8449-6677pt_BR
dc.creator.orcid0000-0002-4346-7941pt_BR
dc.type.formArtigopt_BR
dc.description.otherSponsorshipsem informaçãopt_BR
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.